Email this article Results of a comparative study of the efficacy of once daily darunavir/atazanavir in treatment-naïve patients with HIV infection
- Authors: Moshkovich GF1, Minaeva SV1,2
-
Affiliations:
- ГБУЗ НО "Нижегородский областной центр по профилактике и борьбе со СПИД и инфекционными заболеваниями", Нижний Новгород, Россия
- ГОУ ВПО "Нижегородская медицинская академия" Минздрава России, Нижний Новгород, Россия
- Issue: Vol 86, No 11 (2014)
- Pages: 29-33
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31649
- ID: 31649
Cite item
Full Text
Abstract
AIM. To evaluate the efficacy of boosted darunavir and atazanavir used in antiretroviral therapy (ARVT) regimens for treatment-naïve HIV-infected patients with low baseline immune parameters and a high viral load. MATERIALS AND METHODS. The investigators evaluated the clinical, immunological, and virological efficiency of treatment: the time course of changes in CD4+ lymphocyte levels and viral load at the beginning and at 12, 24, 48, 72, and 96 weeks of antiviral therapy, as well as adverse reactions. RESULTS. The virological effect of once daily darunavir/ritonavir 800/100 mg was highly competitive with that of atazanavir/ritonavir: at 96 weeks of treatment, HIV RNA <120 copies/ml was achieved in 95% of the patients in both treatment groups. A combination of once daily darunavir/ritonavir 800/100 mg ensured a more marked immunological improvement: a difference in the increment (77.1 in 1 µl) of CD4+ lymphocyte count in patients who took darunavir (362.2 in µl) and in those who used atazanavir (285.1 in µl). In the patients who received darunavir, diarrhea, nausea, and headache were observed at the same frequency as in those who had atazanavir. CONCLUSION. The use of the test agents used in the ARVT has shown their efficacy and good tolerability.
Full Text
##article.viewOnOriginalSite##About the authors
G F Moshkovich
ГБУЗ НО "Нижегородский областной центр по профилактике и борьбе со СПИД и инфекционными заболеваниями", Нижний Новгород, Россия
S V Minaeva
ГБУЗ НО "Нижегородский областной центр по профилактике и борьбе со СПИД и инфекционными заболеваниями", Нижний Новгород, Россия; ГОУ ВПО "Нижегородская медицинская академия" Минздрава России, Нижний Новгород, Россия
Email: mistella@yandex.ru
References
- Покровский В.В., Юрин О.Г., Кравченко А.В. и др. Протоколы лечения больных ВИЧ-инфекцией. Эпидемиол и инфекц бол 2011; 3: 4.
- Хоффман К., Рокштро Ю.К. (ред.). Лечение ВИЧ-инфекции. Пер. с англ. М: Р.Валент 2012.
- Бартлетт Дж., Галант Дж., Фам П. Клинические аспекты ВИЧ-инфекции. 2012. Пер. с англ. М: Р.Валент 2012.
- Molina J.M., Andrade-Villanueva J. et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J AIDS 2010; 53: 323-332.
- Squires K.E., Lazzarin A., Gatell J.M. et al. Comparison of once-daily atazanavir with efavirenz each in combination with fixed-dose zidovudin and lamivudine, as initial therapy for patients infected with HIV. J AIDS 2004; 36: 1011-1019.
- Ortiz R., Dejesus E., Khanlou H. et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22: 1389-1397.
- Mills A.M., Nelson M., Jayaweera D. et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir, in treatment-naive HIV-1-infected patients: 96-week analysis. AIDS 2009; 23: 1679-1688.
